Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

Abstract

Copolymer I (Copaxone) was evaluated in a multicenter, placebo-controlled, double-blind trial at 11 US universities. Two hundred and fifty-one relapsing-remitting ambulatory MS patients were randomized to receive 20 mg of copolymer 1 or placebo by daily subcutaneous injection for approximately 30 months. At conclusion, the copolymer 1 group had 32% fewer relapses (P=0.002) and significantly more were relapse-free (P=0.035). Significantly, more patients were receiving copolymer 1 had improved during the study, while more patients on placebo showed neurological decline (P=0.001). There were few side effects and no drug related laboratory abnormalities. Copolymer 1 is being considered by North American and European regulatory agencies for approval as a commercially available agent for the control of multiple sclerosis.

Keywords

Multiple sclerosis copolymer 1 relapse treatment

Get full access to this article

View all access options for this article.

References

1 Teitelbaum D et al. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242–248.

2 Arnon R . (1981) Experimental allergic encephalomyelitis — susceptibility and suppression. Immunol Rev 55: 5–30.

3 Teitelbaum D , Aharoni R , Sela M , Arnon R . (1991) Cross-reactions and specificities of monocloal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 88: 9528–9532.

4 Racke MK , Martin R , McFarland H , Fritz RB . (1992) Copolymer 1-induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J Neuroimmunol 37: 75–84.

5 Abramsky O , Teitelbaum D , Arnon R . (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: Preliminary report. J Neurol Sci 31: 433–438.

6 Bornstein MB et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414.

7 Bornstein MB et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41: 533–539.

8 Johnson K et al. (1995) Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45: 1268–1276.